![Medicinal Cannabis Draws Eyes as Oil Slides and Bond Yields Climb [FTSE AIM UK 50 INDEX]](https://cedclinic.com/wp-content/uploads/2026/06/ced-unsplash-ke6jYtwXDKA-1-150x150.jpg "Medicinal Cannabis Draws Eyes as Oil Slides and Bond Yields Climb [FTSE AIM UK 50 INDEX] 25")
June 17, 2026. 5 regulatory items above the clinical relevance threshold of 40. Sources include Federal Register, regulations.gov, and regulatory RSS feeds. Listed in descending order of relevance score.
The DEA placed four synthetic cannabinoids into Schedule I, classifying them as having a high potential for abuse and no accepted medical use, impacting clinical practice and legal considerations regarding cannabinoid products.
This topic comes up in consultations often.
Dr. Caplan offers clinical context on evolving cannabis policy and its real-world implications for patients.
Book a consultation →The DEA proposes rescheduling FDA-approved products containing marijuana from Schedule I to Schedule III, potentially easing access for clinicians and patients while maintaining federal control.
Read more →Schedules of Controlled Substances: Placement of MDMB-4en-PINACA in Schedule I
The DEA placed synthetic cannabinoid MDMB-4en-PINACA into Schedule I, classifying it as having a high potential for abuse and no accepted medical use, impacting clinical practice and legal considerations regarding cannabinoid products.
Read more →The DEA placed 3-methoxyphencyclidine, a dissociative anesthetic with no accepted medical use, into Schedule I, impacting any potential research involving this substance and clarifying its legal status separate from cannabis.
Read more →Schedules of Controlled Substances: Temporary Placement of Bromazolam in Schedule I
The DEA temporarily placed bromazolam, a benzodiazepine sometimes found as an adulterant in illicit cannabis products, into Schedule I, impacting prescribing, dispensing, and research involving the substance.
Read more →Digest-Level Clinical Commentary
These regulatory actions reflect a bifurcated federal approach where synthetic cannabinoids and novel psychoactive substances face increasingly aggressive scheduling while FDA-approved cannabis-derived medications move toward rescheduling, creating a clarifying but paradoxical landscape for clinical practice. The rescheduling of marijuana-derived pharmaceuticals to Schedule III acknowledges medical utility that cannabis medicine practitioners have long observed clinically, yet the concurrent scheduling of novel synthetics suggests regulatory focus on abuse potential rather than therapeutic applications. For my practice, this signals that evidence-based cannabis medicine will likely receive greater legitimacy through traditional pharmaceutical pathways, while whole-plant cannabis remains in a regulatory gray zone that complicates research, standardization, and consistent patient access.
These regulatory actions reflect ongoing efforts to control the proliferation of synthetic cannabinoids and novel psychoactive substances that circumvent existing drug scheduling laws. The inclusion of multiple synthetic cannabinoid analogs alongside traditional enforcement actions demonstrates a consistent pattern of reactive scheduling to address compounds developed specifically to evade legal restrictions. The concurrent rescheduling of FDA-approved cannabis products to Schedule III represents a significant shift in federal drug policy that may have implications for clinical access and research opportunities for these medications.
💬 Join the Conversation
Have a question about how this applies to your situation? Ask Dr. Caplan →
Want to discuss this topic with other patients and caregivers? Join the forum discussion →
Have thoughts on this? Share it:
